Antibody response against the identified antigens in healthy persons, MGUS patients, and MM patients
| Gene product . | Healthy donors (n = 25) . | MGUS (n = 29) . | MM newly diagnosed (n = 11) . | MM post auto-SCT (n = 11) . | MM refractory (n = 12) . |
|---|---|---|---|---|---|
| OFD1 | 1/25 | 6/29 (20.6%) | 0/11 | 3/11 (27.2%) | 1/12 (8.3%) |
| ZNF292 | 1/25 | 3/29 (10.3%) | 0/11 | 0/10 | 0/12 |
| AKAP11 | 0/25 | 3/29 (10.3%) | 0/11 | 0/10 | 0/12 |
| GPATCH4 | 0/25 | 2/29 (6.8%) | 0/11 | 0/10 | 0/12 |
| SON | 0/25 | 1/29 | 0/11 | 0/10 | 0/12 |
| FAM50A | 0/25 | 1/29 | 0/11 | 0/10 | 0/12 |
| SSSCA1 | 1/25 | 1/29 | 0/11 | 0/10 | 0/12 |
| IFT57/HIPPI | 0/25 | 1/29 | 0/11 | 0/10 | 0/12 |
| IRF2BP2 | 0/25 | 1/29 | 0/11 | 0/10 | 0/12 |
| PSMC1 | 0/25 | 1/29 | 0/11 | 0/10 | 0/12 |
| Gene product . | Healthy donors (n = 25) . | MGUS (n = 29) . | MM newly diagnosed (n = 11) . | MM post auto-SCT (n = 11) . | MM refractory (n = 12) . |
|---|---|---|---|---|---|
| OFD1 | 1/25 | 6/29 (20.6%) | 0/11 | 3/11 (27.2%) | 1/12 (8.3%) |
| ZNF292 | 1/25 | 3/29 (10.3%) | 0/11 | 0/10 | 0/12 |
| AKAP11 | 0/25 | 3/29 (10.3%) | 0/11 | 0/10 | 0/12 |
| GPATCH4 | 0/25 | 2/29 (6.8%) | 0/11 | 0/10 | 0/12 |
| SON | 0/25 | 1/29 | 0/11 | 0/10 | 0/12 |
| FAM50A | 0/25 | 1/29 | 0/11 | 0/10 | 0/12 |
| SSSCA1 | 1/25 | 1/29 | 0/11 | 0/10 | 0/12 |
| IFT57/HIPPI | 0/25 | 1/29 | 0/11 | 0/10 | 0/12 |
| IRF2BP2 | 0/25 | 1/29 | 0/11 | 0/10 | 0/12 |
| PSMC1 | 0/25 | 1/29 | 0/11 | 0/10 | 0/12 |
Phage plaque assay using multiple sera was performed. Screening results of multiple sera from healthy donors, MGUS, and MM patients.